STOCK TITAN

Adia Med (ADIA) Stock News

ADIA OTC

ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.

Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.

Rhea-AI Summary

Adia Med (OTCQB: ADIA) released CEO Larry Powalisz’s open letter reviewing its regenerative medicine business and research progress since January 2024. The company opened its Winter Park clinic, beginning operations and initial patient treatments in January 2025, and attained full SEC reporting status in February 2026.

Adia Med sold a 30% stake in Adia Labs for $1.5 million through its partnership with Live Oak Health, doing business as QCM Biologics, and fully repaid its related-party credit facility. Powalisz separately purchased a 7% economic interest in Adia Labs for $350,000. An autism study began treating its first cohort in May 2026; interim safety data showed no serious adverse events, without establishing efficacy or overall safety. The company plans clinic and distribution expansion, additional studies and a Nasdaq Capital Market uplisting, and has engaged specialized counsel for the uplisting.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.09%
Tags
none
-
Rhea-AI Summary

Adia Med (OTCQB: ADIA) reported no serious adverse events in the first cohort of its randomized pediatric autism study. No events required reporting to the Institutional Review Board. Two children developed mild rashes attributed to topical glutathione spray; both resolved without medical treatment after the spray was stopped.

The Phase 1/2 study compares AdiaVita plus glutathione with glutathione alone in children ages 3 to 12. Enrollment continues on a staggered schedule, with approximately 100 children planned, and first-cohort participants remain in follow-up. The medical director said no efficacy conclusions can be drawn at this time.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
none
-
Rhea-AI Summary

Adia Med (OTCQB: ADIA) completed the sale of an economic interest in Adia Labs to CEO Larry Powalisz for $350,000 in cash. Powalisz purchased seven membership units representing a 7% economic interest at $50,000 per unit. That price matches the per-unit price in the company's recent sale of a 30% interest to Live Oak Health, doing business as QCM Biologics.

Adia Med retains a majority economic interest following closing, subject to the prior Live Oak transaction and any future exercise of Live Oak's option to acquire additional units. Independent directors approved the sale, and Live Oak consented. Use of the proceeds requires independent director approval. The purchased units are intended to carry 7% of total voting power on member matters; the parties will take reasonably necessary steps to reflect that power in company records and the operating agreement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Summary

Adia Med (ADIA) fully repaid and discharged its unsecured revolving credit facility with Chief Executive Officer Larry Powalisz on October 9, 2026.

Total repayment was $934,970.94, covering outstanding principal and accrued interest. The facility had a $1,000,000 commitment and carried 6% annual interest. Remaining obligations consist of the Winter Park clinic lease and one medical equipment lease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
-
Rhea-AI Summary

Adia Med (ADIA) sold a 30% interest in Adia Labs to Live Oak Health, doing business as QCM Biologics, for $1.5 million.

The consideration includes $1.0 million in cash and a $500,000 promissory note payable to Adia Labs. Adia Med retains 70% ownership. Live Oak Health also received a two-year option to acquire an additional 10% stake for $500,000.

The sale is paired with a distribution partnership under which QCM Biologics will sell Adia Labs products through its existing sales force and buy exclusively from Adia Labs for products distributed under the partnership. Adia Med said the arrangement is intended to add outside distribution coverage rather than build it internally. A transaction-related Form 8-K has been filed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
46.53%
Tags
partnership
-
Rhea-AI Summary

Adia Med (ADIA) expanded its Adia Labs portfolio with three products for research and investigational studies.

Adia30M is formulated at 30 million stem cells/TNCs. AdiaClear is an exosome eye-drop and ear product, while AdiaEXO is a one trillion exosome product designed to support a lower price point for studies requiring smaller concentrations. Adia Labs already supplies Adia Med clinics and outside providers. Its products are manufactured and distributed for analytical testing, research use, and Institutional Review Board-approved or similarly authorized protocols.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.07%
Tags
none
Rhea-AI Summary

Adia Med (ADIA) reports that the estimated retail value of biologic inventory at its Adia Labs division now exceeds $1.5 million, reflecting rising demand and expansion of its clinical studies.

Management estimates that Adia Labs’ biologic inventory had an approximate retail value of $380,000 at the end of Q2 2026, with the increase attributed to higher product demand from clinical studies, commercial sales, and expanded supply to partner providers. Adia Labs supplies AdiaVita, the flagship biologic, to company clinics, outside providers, and four active investigational studies in autism spectrum disorder, chronic kidney disease, lower back pain, and additional research. Adia Med expects to launch five more studies later in 2026. As of June 30, 2026, biologic inventory was reported at a U.S. GAAP carrying cost of $140,500, and all products and studies remain investigational and not FDA-approved to diagnose, treat, cure, or prevent disease.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

Adia Med (ADIA) submitted a new osteoarthritis clinical study protocol for its AdiaVita umbilical cord blood-derived stem cell and exosome product to an Institutional Review Board in 2026.

The proposed trial will evaluate a one-time systemic intravenous treatment in adults with osteoarthritis, focusing on safety and potential effects on joint-related inflammation, function, and patient-reported outcomes. Participation is planned under a patient-pay model priced at $5,000 per patient. This is Adia Med's fifth clinical study protocol submission in 2026, and the company plans to submit three to four additional protocols for review before year-end.

The osteoarthritis study remains investigational, is not yet IRB-approved, is not registered on ClinicalTrials.gov, and is not open for enrollment. If approved, Adia Med expects to complete remaining start-up steps, including ClinicalTrials.gov registration, before beginning any patient enrollment. This protocol adds to a 2026 research pipeline that already includes studies in autism spectrum disorder, chronic kidney disease, and lower back pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.31%
Tags
-
Rhea-AI Summary

Adia Med (ADIA) has verified that it meets Nasdaq Capital Market’s shareholder distribution requirement for an initial listing. The company currently has 361 round-lot holders, exceeding Nasdaq’s minimum of 300 shareholders each holding at least 100 unrestricted shares. Adia Med’s OTC Markets security details show about 94.4 million shares outstanding, including approximately 35.8 million unrestricted shares and 23.2 million shares held at DTC as of August 27, 2026.

The company describes this as one completed item on its Nasdaq uplisting checklist but stresses this update is not Nasdaq approval and does not mean all listing standards are satisfied. Remaining requirements include minimum bid price, market value of publicly held shares, financial tests, and corporate governance. Adia Med continues to trade on the OTCQB Venture Market under the symbol ADIA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
Rhea-AI Summary

Adia Med (OTCQB: ADIA) announced that an innovation session at Full Sail University led to the creation of an intern-led social media team spanning YouTube, Meta platforms, TikTok, X, LinkedIn and other channels. Interns will work unpaid in specialized roles such as video, short-form content, design, copy, and community management in exchange for real-world experience, resume credentials, and potential hiring opportunities.

According to the company, a dedicated team member manages a packed content calendar aimed at driving thousands of organic views and increasing visibility among potential patients, investors, partners, and others interested in its regenerative medicine work.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.86%
Tags
none

FAQ

What is the current stock price of Adia Med (ADIA)?

Adia Med (ADIA) last closed at $0.1280.

What is the market cap of Adia Med (ADIA)?

The market cap of Adia Med (ADIA) is approximately $12.1M.